skip to Main Content
 

SmallCap Round Up: Sondrel, Shuka Minerals, Verditek

*

Despite making a solid start, London’s AIM Index has given back most of the day’s gains heading into the close, standing at 751.54 with 10 minutes to go. Some distinctly mixed earnings news from Wall Street appears to be weighing on UK markets as we edge towards the weekend break.

  • Sondrel +101%
  • Shuka Minerals +19%
  • Verditek -23%
  • Hardide -21%

Sondrel [LON:SND] soared more than 100% off the back of media speculation that the specialist chip maker was behind Elon Musk’s brain implant Neuralink program. The company issued a speeding ticket in reaction to the move but won’t divulge its customer list.


Shuka Minerals [LON:SKA] was 19% higher running into the close. There’s no news here and the stock continues to trade in the recently established range. Read across from other miners may be supporting or there could be news incoming.

Verditek [LON:VDTK] slumped 23% on the day, extending the losses which were initiated yesterday on the news of a proposed disposal that could leave the company with a decimated asset base.

Hardide [LON:HDD] was down 21% heading into the close, as investors digested this morning’s FY23 results and FY24 trading update. A notable increase in revenues and a significant improvement in margin both combined to halve pre-tax losses. However the note highlights how it has been a slower than expected start to the new trading year, with cash being depleated as a result. Investors are being tapped for fresh cash.

Like this article? Sign up to our free newsletter.

This article does not constitute investment advice. Do your own research or consult a professional advisor.

The Armchair Trader's 'How to' Guides

Read our latest in-depth company reports

Detailed reviews of selected companies and investment trusts.

Listen to our latest podcast episodes

Thanks to our Partners

Our partners are established, regulated businesses and we are grateful for their support.

Aquis
FP Markets
IG
Pepperstone
WisdomTree
CME Group
Back To Top